Re-Medical CBD for Next Generation of Pain Killers Delivered to World’s Sixth Largest Economy and Internationally
TEMECULA, CA, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Hop-on, Inc. (OTC Pink: HPNN) announced today its subsidiary, Re-Medical, Inc., has set up distribution of cannabis-derived product offerings, secured a million dollar line of credit and is obtaining additional financing for expansion of operations. Re-Medical has a variety of CBD and full-spectrum marijuana products for delivery to licensed facilities.
In November this year, eight states passed new marijuana legalization. Beginning January 1st, 2018 California’s legal marijuana industry will take full effect. California has the sixth largest economy in the world, and according to the Los Angeles Times “California's new pot economy [is] valued at $7 billion.”
Re-Medical has developed the “next generation” painkiller medication, with oral, transdermal, and injectable delivery of full-spectrum standardized formulations of cannabidiol (CBD) and/or tetrahydrocannabinol (THC) for pain related ailments. Phase 1 and Phase 2 testing of numerous cannabinoid pain treatments have already cleared the FDA.
Hundreds of millions of prescriptions for opioid painkillers were filled this last year – more than enough for every adult in the United States to take them for at least a month. Those numbers have built incredible wealth for the companies manufacturing these drugs, at the expense of the general public. Cannabinoid pain treatments can be just as effective as opioid-based medication, with a favorable safety profile, and without the addictive side effects.
Re-Medical is licensing for production and distribution of the Company’s various revolutionary organic and solvent-free standardized cannabinoid formulations and products. Partnerships, technology licensing agreements, and distribution contracts are being offered to authorized marijuana cultivators, producers of infused products, medical marijuana facilities, and retailers in California, as well as other states and foreign jurisdictions.
Re-Medical's mission is to provide solutions for patients to use cannabis as a nutraceutical alternative to traditional or prescription medications.
Re-Medical, Inc. is a Hop-on company focused on delivering Next Generation Pain Killers products such as cannabis, utilizing transdermal patches and other novel technologies. The company has developed and isolated the benefits of cannabis and other vital plant extracts for best patient care. There are an estimated 80+ cannabinoids found in cannabis, each providing distinctive neuropathic effects. The company is currently applying for patents regarding the delivery of cannabis via transdermal patches. Re-Medical patches offer cost effective, accurate and clean delivery of these unique compounds.
Hop-on, Inc. (HPNN.PK) is a global ODM and OEM manufacturer of electronics, based in the United States. Over the past 20 years, Hop-on has successfully secured essential patents for mobile communications and computing technologies, and is respected for developing the world’s first disposable cell phone. Hop-on's focus on smartphones and innovative mobile device applications is bringing cost friendly solutions to today's demanding world market. Hop-on is also diversified in delivering cannabis remedies. For more information, please visit www.re-medical.com
Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.